European Journal of Clinical Pharmacology

, Volume 64, Issue 2, pp 173–181 | Cite as

The future of pharmacovigilance: a personal view

Review Article

References

  1. 1.
    Moore N et al (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 2(8463):1056–1058PubMedCrossRefGoogle Scholar
  2. 2.
    Royer R (1990) Pharmacovigilance. The French system. Drug Safety 5(Suppl 1):137–140Google Scholar
  3. 3.
    Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 279(15):1200–1205PubMedCrossRefGoogle Scholar
  4. 4.
    Pirmohamed MJS, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15–19PubMedCrossRefGoogle Scholar
  5. 5.
    Medawar C, Hardon A (2004) Medicines out of control? – Antidepressants and the conspiracy of goodwill. Aksant Academic Publishers, Amsterdam, p. 260Google Scholar
  6. 6.
    Radoilska L, Scott D (2005) Trust in the pharmaceutical industry: a philosophical perspective. University of Cambridge, CambridgeGoogle Scholar
  7. 7.
    Nelson KM, Talbert RL (1996) Drug-related hospital admissions. Pharmacotherapy 16(4):701–707PubMedGoogle Scholar
  8. 8.
    Lindquist M (2003) Seeing and observing in international pharmacovigilance - achievements and prospects in worldwide drug safety. University of Nijmegen, NijmegenGoogle Scholar
  9. 9.
    Norén GN, Bate A, Orre R (2005) A hit-miss model for duplicate detection in the WHO drug safety database. ACM, New YorkGoogle Scholar
  10. 10.
    Norén GA (2007) Statistical methods for knowledge discovery in adverse drug reaction surveillance, in Department of Mathematics. Stockholm Univeristy, Stockholm, p. 41Google Scholar
  11. 11.
    Bate A (2003) The use of a Bayesian confidence propagation neural network in pharmacovigilance, in Department of Pharmacology and Clinical Neuroscience. Umeå University, UmeåGoogle Scholar
  12. 12.
    Edwards I (2005) The WHO World Alliance for Patient Safety: a new challenge or an old one neglected? Drug Safety 28(5):379–386PubMedCrossRefGoogle Scholar
  13. 13.
    Bowdler J (1997) Effective communications in pharmacovigilance. 1 ed. Communications in Pharmacovigilance, Vol. 1. W Lake Ltd, Birmingham, England, p 89Google Scholar
  14. 14.
    Adice International Limited (2007) The Erice manifesto: for global reform of the safety of medicines in patient care. Drug Saf 30(3):187–190CrossRefGoogle Scholar
  15. 15.
    Wright A (2002) Dialogue in pharmacovigilance. Communication in pharmacovigilance, ed. W. A. The Uppsala Monitoring Centre, UppsalaGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.The WHO Foundation Collaborating Centre for International Drug MonitoringUppsalaSweden

Personalised recommendations